Sciclone May Yet Best The ShortsBy
The bold bears and raging bulls battling over SciClone Pharmaceuticals are likely to engage in another big fight soon. The company's flagship drug, Alpha Thymosin 1, has been under attack by the shorts, who say clinical studies have been limited and "overly optimistic." SciClone argues that its drug is effective against infectious diseases, such as hepatitis.
To continue reading this article you must be a Bloomberg Professional Service Subscriber.
If you believe that you may have received this message in error please let us know.